PT Ferron Par Pharmaceuticals, one of a Dexa Group company, achieved the Primaniyarta Award 2017 in the category of the New Market Pioneer. The award was granted by the President of the Republic of Indonesia, Ir. H. Joko Widodo to the President Director of PT Ferron Par Pharmaceuticals, Krestijanto Pandji, in the opening ceremony of the Indonesia Trade Expo in ICE Bumi Serpong Damai, Banten, on Wednesday, October 11, 2017.
Primaniyarta is the highest award that was given by the Indonesian Government to the exporter that was considered accomplished in the field of export and could become an example for other exporters. The Primaniyarta Award is an event that is routinely held by the government through the Directorate General of National Export Development of the Ministry of Commerce of the Republic of Indonesia.
Since 2014, the Primaniyarta Award management has been grouped into four categories which are; Performer Exporter, Exporter of Global Brand Development, Leading Potential Exporter, and the New Market Pioneer Exporter. From hundreds of national exporter companies that were competing in the Primaniyarta 2017 event, 22 finalists from all categories were generated.
In the New Market, Pioneer category at the 2017 Primaniyarta event, four finalists emerge after a series of judging. Ferron, as one of the finalists in this category, became the best finalist and was entitled to receive the award directly from the President of the Republic of Indonesia, Joko Widodo.
Being a Global PlayerFerron’s success to achieve the Primaniyarta Award 2017 is because of its tenacity and persistence to penetrate the United Kingdom (UK) market. For the pharmaceutical industry, the UK is a highly regulated market with very strict rules in quality. For more than three years, PT Ferron Par Pharmaceuticals trying to learn and understand the necessary factors to be able to enter the European market.
Some of the key factors are competitive price, a production facility with good systems and quality culture, and competence in product development that complies with the regulation rules and standards in Europe. Ferron also committed in the search of raw materials source which complies to the quality requirement, meet the requirements of good supporting documents, free from copyright issues, and consistent in building the commitment of product development competence with a regulatory habitat which supported with research and development infrastructure and competent human resources.
This is the strategy developed by Ferron to penetrate the UK pharmaceutical market, which culminates with a satisfactory predicate for the audit result of the UK Medicine and Healthcare Products Regulatory Agency (MHRA) in January 2008. In March 2008, PT Ferron Par Pharmaceuticals received the Good manufacturing practices (GMP) certificate from MHRA for solid dosage. Finally, on July 21, 2008, PT Ferron Par Pharmaceuticals successfully perform its first export to the UK. This success has made Ferron as the first pharmaceutical company from Indonesia to penetrate the UK market.
Now, Ferron’s products have become necessary products in the UK. Ferron has become the second pharmaceutical company in the UK with a 25 % market share. One of Ferron’s products, Metformin Sustain Release or well known as Glucient SR used in the UK National Health Care System. This product is used to treat diabetic patients in the UK, which its prevalence reaches 6% of the total population.
Not only in the UK, Ferron also exported its products to other highly regulated markets such as USA, Canada, Japan, Australia, and some other European Countries. Besides developing the domestic market, Ferron also penetrates foreign markets such as Holland, Poland, Belarus, and Germany. Corporate Communications Dexa Group